TY  - JOUR
T1  - REfinement of adjuvant therapy for pancreatic cancer
AU  - O’Reilly EM
Y1  - 2010/09/08
N1  - 10.1001/jama.2010.1302
JO  - JAMA
SP  - 1124
EP  - 1125
VL  - 304
IS  - 10
N2  - 
Adenocarcinoma of the pancreas is arguably the most challenging of human malignancies. Approximately 43 000 patients will be diagnosed with pancreatic cancer in the United States in 2010, and during this same period approximately 37 000 will die from this malignancy.1 About 15% to 20% of patients (6500-8600) diagnosed each year have localized disease that is amenable to potentially curative surgery.2 Despite such surgery, nearly 85% of patients are destined to experience relapse and die of their disease.3- 4 Therefore, adjuvant therapy is an appealing therapeutic option designed to eradicate occult metastatic disease, delay disease recurrence, and enhance overall survival.

SN  - 0098-7484
M3  - doi: 10.1001/jama.2010.1302
UR  - http://dx.doi.org/10.1001/jama.2010.1302
ER  -